Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The only FDA-label-relevant clinical claim (treatment of overactive bladder) is supported by the Indications and Usage section. Other claims relate to pricing/insurance/formulary status, which are absent from the provided label and are not contradicted by it.
Category Scores
Accurate Statements
Trospium ER (Sanctura XR) is a medication used to treat overactive bladder.
Label 1 INDICATIONS AND USAGE: indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Unsupported Statements
Without insurance, the retail price for a 30-day supply of 60 mg extended-release trospium capsules can range from approximately $100 to $200 or more.
Pricing and cost estimates are not present in the provided FDA label sections.
Prices for trospium ER can vary by dosage, quantity, insurance coverage, and the pharmacy where it is purchased.
No retail pricing methodology or variability by pharmacy/quantity is stated in the provided FDA label sections.
Generic versions of trospium ER are generally less expensive than brand-name medications.
Comparative pricing between generic and brand is not included in the provided FDA label sections.
Without insurance, a 30-day supply of generic trospium ER (typically 60 mg) might cost between $40 and $100.
No generic pricing/cost range is provided in the provided FDA label sections.
Insurance coverage for trospium ER varies by plan.
Coverage/formulary statements are not included in the provided FDA label sections.
Many insurance providers include trospium ER on their formularies.
Formulary inclusion claims are not included in the provided FDA label sections.
Contradictions
Important Omissions
If the goal is FDA-label-complete promotional accuracy, the response does not include contraindications, warnings/precautions, drug interactions, adverse reactions, or dosing/administration details from the label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only supported clinical claim concerns indication. The other claims are non-label pricing/insurance statements and do not assert dosing, contraindications, or safety risks.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several claims are not supported by the provided FDA label (pricing/insurance/formulary).
Suggested Improvement
Clearly mark non-label information (pricing/insurance/formulary) as external to FDA-approved prescribing information, and limit FDA-label claims to the supported indication statement unless additional label-supported content is provided.